RCE 0.97% 52.0¢ recce pharmaceuticals ltd

Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial, page-5

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 599 Posts.
    lightbulb Created with Sketch. 361
    Oh, Recce. You never fail to disappoint. I count three bald-faced lies in just the first two lines of this announcement!
    The Donald Trump of the ASX.

    Lie 1: RCE call it a "Phase I/II" but it is just a phase 1.

    Lie 2: RCE say they have dosed "clinical subjects" but they are dosing healthy subjects.

    Lie 3: They say it's a "UTI/Urosepsis" clinical trial but it's a safety / pharmacokinetics trial.

    Source: Their own trial data
    https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385744
 
watchlist Created with Sketch. Add RCE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.